Long-term Follow Up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-mutated Melanoma: Final Results of the COMBI-AD Study.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined